NCT04327700 2026-03-05
Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib
Wake Forest University Health Sciences
Phase 2 Terminated
Clinical Trials
15 trialsNCT03563157 2024-12-11
QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT02581059 2024-06-26
Efficacy of Ginseng for Patients on Regorafenib
Wake Forest University Health Sciences
Phase 2 Terminated
NCT03555149 2023-11-07
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)
Hoffmann-La Roche
Phase 1/2 Terminated
NCT02383433 2023-10-23
Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer
Case Comprehensive Cancer Center
Phase 2 Terminated
NCT03099486 2022-02-07
Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRC
Fox Chase Cancer Center
Phase 2 Terminated
NCT02587650 2020-01-27
Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma
University of California, San Francisco
Phase 2 Terminated
NCT02402036 2019-01-29
A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer
Georgetown University
Phase 2 Terminated
NCT02234180 2018-10-17
Regorafenib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction Who Have Completed Chemoradiation Therapy and Surgery
Academic and Community Cancer Research United
Phase 2 Terminated
NCT02119676 2018-02-13
Study of Ruxolitinib in Colorectal Cancer Patients
Incyte Corporation
Phase 2 Terminated
NCT02168777 2018-01-26
Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer
Bayer
Phase 1 Terminated
NCT02241720 2018-01-11
Regorafenib Second Line Treatment of Metastatic or Advanced Upper GI Cancers
University of Utah
Phase 2 Terminated
NCT01939223 2017-10-20
COAST
Bayer
Phase 3 Terminated
NCT02287025 2017-10-19
SMART
Bayer
Phase 4 Terminated
NCT02278783 2017-10-06
Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer
University of Utah
Phase 2 Terminated